Modality
Multispecific
MOA
TYK2i
Target
PRMT5
Pathway
PI3K/AKT
MCLCKDAML
Development Pipeline
Preclinical
~Aug 2017
→ ~Nov 2018
Phase 1
Feb 2019
→ Feb 2026
Phase 1Current
NCT03330398
503 pts·CKD
2021-08→2026-02·Active
NCT08148854
1,877 pts·AML
2019-02→TBD·Not yet recruiting
2,380 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-02-022mo agoInterim· CKD
Trial Timeline
2019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026
P1
Not yet…
P1
Active
Catalysts
Interim
2026-02-02 · 2mo ago
CKD
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03330398 | Phase 1 | CKD | Active | 503 | CfB |
| NCT08148854 | Phase 1 | AML | Not yet recr... | 1877 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| Nidasacituzumab | Eli Lilly | Approved | CFTR | |
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| MRK-2473 | Merck & Co | Phase 1/2 | Nectin-4 | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 |